恶性肿瘤的细胞免疫疗法-它们是如何起作用的,有什么副作用?]

IF 0.2 Q4 MEDICINE, GENERAL & INTERNAL
THERAPEUTISCHE UMSCHAU Pub Date : 2023-10-01
Heinz Läubli
{"title":"恶性肿瘤的细胞免疫疗法-它们是如何起作用的,有什么副作用?]","authors":"Heinz Läubli","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The advent of immunotherapy has brought about a revolutionary shift in the treatment of cancer patients, significantly improving their outcomes. However, it is disheartening that not all patients can benefit from the currently available immunotherapies. Fortunately, cellular immunotherapies have emerged as a promising alternative. Among these approaches, the use of ex vivo activated and expanded tumor-infiltrating lymphocytes (TIL) has shown promise, particularly in patients with immunogenic cancers like melanoma. Moreover, advancements in genetic manipulation techniques have enabled the engineering of T cells with synthetic chimeric antigen receptors (CAR) capable of recognizing specific targets, such as CD19-positive cancers like B-cell leukemias and lymphomas. These cellular immunotherapies have made their way into clinical practice, although they may occasionally give rise to severe and previously unknown side effects. This review aims to provide an in-depth understanding of these therapies while discussing the associated side effects and their management strategies.</p>","PeriodicalId":44874,"journal":{"name":"THERAPEUTISCHE UMSCHAU","volume":"80 8","pages":"348-352"},"PeriodicalIF":0.2000,"publicationDate":"2023-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Cellular immunotherapies for malignancies - How do they work and what are the side effects?]\",\"authors\":\"Heinz Läubli\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The advent of immunotherapy has brought about a revolutionary shift in the treatment of cancer patients, significantly improving their outcomes. However, it is disheartening that not all patients can benefit from the currently available immunotherapies. Fortunately, cellular immunotherapies have emerged as a promising alternative. Among these approaches, the use of ex vivo activated and expanded tumor-infiltrating lymphocytes (TIL) has shown promise, particularly in patients with immunogenic cancers like melanoma. Moreover, advancements in genetic manipulation techniques have enabled the engineering of T cells with synthetic chimeric antigen receptors (CAR) capable of recognizing specific targets, such as CD19-positive cancers like B-cell leukemias and lymphomas. These cellular immunotherapies have made their way into clinical practice, although they may occasionally give rise to severe and previously unknown side effects. This review aims to provide an in-depth understanding of these therapies while discussing the associated side effects and their management strategies.</p>\",\"PeriodicalId\":44874,\"journal\":{\"name\":\"THERAPEUTISCHE UMSCHAU\",\"volume\":\"80 8\",\"pages\":\"348-352\"},\"PeriodicalIF\":0.2000,\"publicationDate\":\"2023-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"THERAPEUTISCHE UMSCHAU\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"MEDICINE, GENERAL & INTERNAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"THERAPEUTISCHE UMSCHAU","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

摘要

免疫疗法的出现给癌症患者的治疗带来了革命性的转变,显著改善了他们的预后。然而,令人沮丧的是,并非所有患者都能从目前可用的免疫疗法中受益。幸运的是,细胞免疫疗法已经成为一种很有前途的替代疗法。在这些方法中,体外激活和扩大肿瘤浸润淋巴细胞(TIL)的使用已显示出希望,特别是在患有免疫原性癌症(如黑色素瘤)的患者中。此外,基因操作技术的进步使得T细胞工程与合成嵌合抗原受体(CAR)能够识别特定的目标,如cd19阳性的癌症,如b细胞白血病和淋巴瘤。这些细胞免疫疗法已经进入临床实践,尽管它们偶尔会产生严重的和以前未知的副作用。本综述旨在深入了解这些治疗方法,同时讨论相关的副作用及其管理策略。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
[Cellular immunotherapies for malignancies - How do they work and what are the side effects?]

Introduction: The advent of immunotherapy has brought about a revolutionary shift in the treatment of cancer patients, significantly improving their outcomes. However, it is disheartening that not all patients can benefit from the currently available immunotherapies. Fortunately, cellular immunotherapies have emerged as a promising alternative. Among these approaches, the use of ex vivo activated and expanded tumor-infiltrating lymphocytes (TIL) has shown promise, particularly in patients with immunogenic cancers like melanoma. Moreover, advancements in genetic manipulation techniques have enabled the engineering of T cells with synthetic chimeric antigen receptors (CAR) capable of recognizing specific targets, such as CD19-positive cancers like B-cell leukemias and lymphomas. These cellular immunotherapies have made their way into clinical practice, although they may occasionally give rise to severe and previously unknown side effects. This review aims to provide an in-depth understanding of these therapies while discussing the associated side effects and their management strategies.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
THERAPEUTISCHE UMSCHAU
THERAPEUTISCHE UMSCHAU MEDICINE, GENERAL & INTERNAL-
CiteScore
0.50
自引率
0.00%
发文量
75
期刊介绍: Monat für Monat ein aktuelles Thema der praktischen Medizin - als Sammlung ein hochaktuelles Nachschlagewerk.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信